ArticleFrontiers in nutrition2026
High-fat diet, triglyceride glucose index, and gastrointestinal cancer: integrative insights from human and animal studies.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High-fat diet (HFD) exposure has been associated with an increased risk of gastrointestinal (GI) cancers; however, the metabolic and inflammatory mechanisms underlying this association remain incompletely understood. Identifying clinically accessible biomarkers that capture diet-induced metabolic stress may improve early risk stratification and prevention strategies. Methods: Data were obtained from the National Health and Nutrition Examination Survey (NHANES, 2003-2020) and the Global Burden of Disease (GBD) 2021 dataset. HFD-related metabolic exposure was characterized using eight lipid-related obesity indices, including body mass index (BMI), waist-to-height ratio (WHtR), lipid accumulation product (LAP), visceral adiposity index (VAI), triglyceride-glucose index (TyG), TyG-WHtR, waist circumference (WC), and TyG-BMI. Threshold effects of TyG were evaluated, and mediation analyses were performed to assess the roles of the systemic immune-inflammation index (SII) and neutrophil-to-lymphocyte ratio (NLR). Complementary animal experiments were conducted to examine changes in TyG levels, gastrointestinal histopathology, and serum carbohydrate antigen 19-9 (CA19-9). Results: Elevated TyG levels were significantly associated with increased GI cancer risk. A nonlinear relationship was identified, with a threshold effect at TyG = 9.657; below this threshold, the association exhibited a dose-dependent pattern. Mediation analyses indicated that SII and NLR partially mediated the TyG-GI cancer association, accounting for 1.6 and 2.8% of the total effect, respectively. Stratified analyses revealed significant heterogeneity across demographic subgroups. In animal models, HFD exposure resulted in elevated TyG levels, gastrointestinal mucosal injury, and increased tumor-associated biomarkers, consistent with the development of precancerous lesions. Conclusion: The findings identify the TyG index as a practical and biologically relevant marker linking HFD-induced metabolic dysregulation to GI cancer risk, with systemic inflammation serving as a partial mediator. The integration of population-based analyses with experimental evidence underscores the potential utility of TyG in metabolic risk assessment and precision prevention strategies for GI cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.